PMPam K. Mangat

Pam K. Mangat

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Pam K. Mangat has a total of 196 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Palbociclib in Patients With Ovarian Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study.

    by Dan S Veljovich, Michael Rothe, Elizabeth Garrett-Mayer, Hussein M Ali-Ahmad, R Wendel Naumann, Jean Siedel, John K Chan, Andrew Gregory, Evan Pisick, Bamidele Adesunloye, et al.

    The Targeted Agent and Profiling Utilization Registry Study is a phase II basket trial evaluating the antitumor activity of commercially available targeted agents in patients with advanced cancer and genomic alterations. Results of a cohort of patients with ovarian cancer (OC) with CDKN2A alterations treated with palbociclib are reported. Eligible patients had advanced OC, measurable disease (RECIST), Eastern Cooperative Oncology Group performance status 0-2, adequate organ function, tumors with CDKN2A alterations, and no remaining standard treatment options. The primary end point was disease control (DC), defined as objective response (OR) or stable disease (SD) of at least 16+ weeks duration (SD16+). Simon two-stage design with a null DC rate of 15% versus 35% (power = 0.85; α = .10) was used. Secondary end points included OR, progression-free survival (PFS), overall survival (OS), duration of response, duration of SD, and safety. Twenty-eight patients were enrolled from February 2017 to April 2023, and all had OC with a CDKN2A alteration (loss [n = 21], mutation [n = 5], and loss and mutation [n = 2]). One patient was not evaluable for efficacy because of an excluded genomic finding. Three patients had a partial response and seven had SD16+ for DC and OR rates of 38% (90% CI, 25 to 100) and 11% (95% CI, 2 to 29), respectively. The null hypothesis of 15% DC rate was rejected (P = .004). The median PFS was 8 weeks (95% CI, 8 to 18) and the median OS was 33 weeks (95% CI, 24 to 73). Nineteen patients (68%) had at least one treatment-related grade 3-4 adverse event (AE) or serious AE including anemia, dyspnea, fatigue, leukopenia, neutropenia, and thrombocytopenia. Palbociclib met the prespecified criteria to declare a signal of activity in patients with OC and CDKN2A alterations.

  • Nivolumab Plus Ipilimumab in Patients With Solid Tumors With High Tumor Mutation Burden: Results From the Targeted Agent and Profiling Utilization Registry Study

    by Erin F. Cobain, Michael Rothe, Elizabeth Garrett-Mayer, Timothy L. Cannon, John K. Chan, Kathryn F. Mileham, Bamidele Adesunloye, Carmen J. Calfa, Olatunji B. Alese, Kathleen Yost Butler, et al.

    PURPOSE: Targeted Agent and Profiling Utilization Registry is a phase II basket trial evaluating the antitumor activity of targeted agents in patients with advanced cancer and genomic alterations. Results of three cohorts of patients with colorectal cancer (CRC), breast cancer (BC), and other solid tumors (histology-pooled [HP]) with high tumor mutation burden (HTMB) treated with nivolumab plus ipilimumab (N + I) are reported. METHODS: Eligible patients had tumors with HTMB (≥10 mutations per megabase), measurable disease (RECIST), Eastern Cooperative Oncology Group performance status 0-2, adequate organ function, and no standard treatment options. The primary end point was disease control (DC), defined as objective response (OR) or stable disease (SD) of at least 16 weeks duration. For histology-specific cohorts, Simon's two-stage design was based on a null DC rate of 15% versus 35% (power = 0.85; α = .10). For the HP cohort, the hypothesized null DC rate of 15% was evaluated by a one-sided exact binomial test (α = .10). Secondary end points were OR, progression-free survival, overall survival, duration of response, duration of SD, and safety. RESULTS: Patients with CRC (N = 12), BC (N = 13), or other advanced cancers (N = 26) with HTMB were enrolled. The CRC cohort failed to reach the predetermined efficacy threshold to warrant expansion at the end of stage I. The BC cohort expanded to stage II but closed by company request before achieving the planned sample size. The DC rates (one-sided 90% CI) for BC and HP cohorts were 33% (15-100, P = .0976) and 32% (20-100), respectively. The null hypothesized 15% DC rate was rejected for the BC and HP cohorts but not the CRC cohort. Nineteen patients experienced treatment-related grade 3 adverse events (AE) or serious AEs. CONCLUSION: N + I demonstrated antitumor activity in patients with tumors with HTMB in the BC and HP cohorts but not the CRC cohort.

  • Pertuzumab and Trastuzumab in Patients With ERBB2/3 -Altered Urothelial or Ovary/Fallopian Tube Cancer: Results From the Targeted Agent and Profiling Utilization Registry Study

    by John K. Chan, Michael Rothe, Elizabeth Garrett-Mayer, Evan Pisick, Pooja Ghatalia, Andrew Gregory, Mollie Deshazo, Kathryn F. Mileham, Martina C. Murphy, Olatunji B. Alese, et al.

    PURPOSE: TAPUR is a phase II basket trial evaluating the antitumor activity of commercially available targeted agents in patients with advanced cancer and genomic alterations. Results of two cohorts of patients with urothelial (UC) or ovarian/fallopian tube cancer (OC/FTC) with ERBB2/3 alterations treated with pertuzumab plus trastuzumab (P + T) are reported. METHODS: Eligible patients had advanced cancer, measurable disease (RECIST), Eastern Cooperative Oncology Group performance status 0-2, adequate organ function, tumors with ERBB2/3 alterations, and no standard treatment options. The primary end point was disease control (DC), defined as objective response (OR) or stable disease (SD) of at least 16+ weeks duration. Simon's two-stage design is based on a null DC rate of 15% versus 35% (power = 0.85; α = .10). Secondary end points included OR, progression-free survival (PFS), overall survival (OS), duration of response, duration of SD, and safety. RESULTS: Patients with UC (n = 28) or OC/FTC (n = 25) with ERBB2/3 alterations were enrolled from March 2017 to June 2023. In the UC cohort, the DC and OR rates were 37% (90% CI, 24 to 100) and 25% (95% CI, 11 to 45), respectively. The null hypothesis of 15% DC rate was rejected ( P = .005). In the OC/FTC cancer cohort, the DC and OR rates were 23% (90% CI, 9 to 100) and 8% (95% CI, 1 to 26), respectively. The null hypothesis of 15% DC rate was not rejected ( P = .35). Six patients had at least one grade 3-5 adverse event (AE) or serious AE at least possibly related to treatment. CONCLUSION: The combination of P + T met prespecified criteria to declare a signal of activity in patients with UC with ERBB2/3 alterations, but not in patients with OC/FTC.

  • Temsirolimus in Patients With Solid Tumors With PIK3CA Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study

    by Evan Pisick, Michael Rothe, Elizabeth Garrett-Mayer, Gordan Srkalovic, John K. Chan, Carmen J. Calfa, Charles A. Leath, Alissa S. Marr, Philip J. Gold, Erin K. Crane, et al.

    PURPOSE: TAPUR is a phase II basket trial evaluating the antitumor activity of commercially available targeted agents in patients with advanced cancer and genomic alterations who have no standard treatments available. Results of four cohorts of patients with PIK3CA -mutated tumors treated with temsirolimus are reported: breast cancer (BC), colorectal cancer (CRC), uterine cancer (UC) and other solid tumors (histology-pooled [HP]). METHODS: Eligible patients had advanced solid tumors, measurable disease (RECIST), Eastern Cooperative Oncology Group performance status 0-2, adequate organ function, and no standard treatment options. The primary end point was disease control (DC), defined as objective response (OR) or stable disease (SD) of at least 16 weeks duration. For the histology-specific cohorts, Simon's two-stage design was based on a null DC rate of 15% versus 35% (power = 0.85; α = .10). For the HP cohort, the hypothesized null DC rate of 15% was rejected if the lower limit of a one-sided 90% CI was >15%. Secondary end points were OR, progression-free survival, overall survival, duration of response, duration of SD, and safety. RESULTS: Patients with PIK3CA -mutated BC (N = 12), CRC (N = 11), UC (N = 30), or other advanced cancers (HP cohort; N = 30) were enrolled. The BC and CRC cohorts did not reach the criteria to expand to stage II and were closed for futility. The DC rates with one-sided 90% CI were 37% (23 to 100, P = .0074) and 31% (20 to 100) for the UC and HP cohorts, respectively. The null hypothesized 15% DC rate was rejected for the UC and HP cohorts but not for the BC and CRC cohorts. Twenty-nine of 83 patients (35%) experienced treatment-related grade 3 adverse events (AEs) or serious AEs. CONCLUSION: Temsirolimus demonstrated antitumor activity in patients with PIK3CA -mutated cancer within the UC and HP cohorts but not the BC or CRC cohorts.

  • Olaparib in Patients With Solid Tumors With ATM Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study

    by Daniel R. Carrizosa, Michael Rothe, Pam K. Mangat, Elizabeth Garrett-Mayer, Deepti Behl, Bamidele Adesunloye, Evan Pisick, Kathleen W. Beekman, Efrat Dotan, Mehmet Akce, et al.

    PURPOSE: The Targeted Agent and Profiling Utilization Registry Study is a phase II basket trial evaluating the antitumor activity of targeted agents in patients with advanced cancer and genomic alterations. Results of four cohorts of patients with ATM -altered tumors treated with olaparib are reported: colorectal cancer (CRC), lung cancer (LC), pancreatic cancer (PC), and other solid tumors (histology-pooled, HP). METHODS: Eligible patients had advanced solid tumors, measurable disease (RECIST), Eastern Cooperative Oncology Group performance status 0-2, adequate organ function, and no standard treatment options. The primary end point was disease control (DC), defined as objective response (OR) or stable disease (SD) of at least 16 weeks duration. For histology-specific cohorts, Simon's two-stage design was based on a null DC rate of 15% versus 35% (power = 0.85; α = .10). For the HP cohort, the hypothesized null DC rate of 15% was rejected if the lower limit of a one-sided 90% CI was >15%. Secondary end points were OR, progression-free survival, overall survival, duration of response or SD, and safety. RESULTS: Patients with CRC (n = 30), LC (n = 20), PC (n = 28), or other advanced cancers (n = 38) with ATM alterations were enrolled. The DC rates were 23% (one-sided 90% CI, 8 to 100; P = .38), 45% (one-sided 90% CI, 32 to 100; P = .0004), 28% (one-sided 90% CI, 14 to 100; P = .14), and 25% (one-sided 90% CI, 16 to 100), respectively. The null hypothesized 15% DC rate was rejected for the LC and HP cohorts but not the CRC and PC cohorts. Twenty of 116 patients (17%) experienced treatment-related grade 3 adverse events (AE) or serious AEs. CONCLUSION: Olaparib met the prespecified criteria to declare a signal of activity in patients with ATM -altered cancer within the LC and HP cohorts but not the CRC or PC cohorts.

  • Olaparib in Patients With Solid Tumors With BRCA1/2 Alterations: Results From The Targeted Agent and Profiling Utilization Registry (TAPUR) Study

    by Tareq Al Baghdadi, Michael Rothe, Pam K. Mangat, Elizabeth Garrett-Mayer, Oxana V. Crysler, Kathryn F. Mileham, Laura Catherine Farrington, Bamidele Adesunloye, Stephanie A. Dublis, Igor Astsaturov, et al.

    PURPOSE: The Targeted Agent and Profiling Utilization Registry Study is a phase II basket trial evaluating the antitumor activity of targeted agents in patients with advanced cancer and genomic alterations. Results of five cohorts of patients with BRCA1/2 -mutated solid tumors treated with olaparib are reported: breast cancer (BC), biliary tract cancer (BTC), lung cancer (LC), uterine cancer (UC), and other solid tumors (histology-pooled [HP]). METHODS: Eligible patients had advanced tumors, measurable disease (RECIST), Eastern Cooperative Oncology Group performance status 0-2, adequate organ function, and no standard treatment options. The primary end point was disease control (DC), defined as complete or partial response or stable disease (SD) of at least 16-weeks duration. For histology-specific cohorts, Simon two-stage design is based on a null DC rate of 15% versus 35% (power = 0.85; α = .10). Cohorts that were closed before achieving the planned stage II sample size were analyzed using a one-sided exact binomial test. For the HP cohort, the hypothesized null DC rate of 15% was rejected if the lower limit of a one-sided 90% CI was >15%. Secondary end points were objective response, progression-free survival, overall survival, duration of response or SD, and safety. RESULTS: Patients with BC (n = 28), BTC (n = 19), LC (n = 25), UC (n = 15), or other advanced cancers (n = 32) with BRCA1/2 alterations were enrolled. The DC rates with one-sided 90% CI were 69% (55-100, P < .001), 50% (32-100, P = .0008), 41% (26-100, P = .0025), 47% (28-100, P = .0036), and 41% (29-100), respectively. The null hypothesized 15% DC rate was rejected for all cohorts. Thirty-six of 119 patients experienced treatment-related grade 3-4 adverse events (AEs) or serious AEs. CONCLUSION: Olaparib met prespecified criteria to declare a signal of activity in patients with various advanced BRCA1/2 -altered solid tumors.


  • Open Access

    Prevalence of targetable genomic alterations among a diverse population participating in the ASCO TAPUR Study

    by Pam K. Mangat, M. Kelsey Kirkwood, Dominique C. Hinshaw, Elizabeth Garrett-Mayer, Richard L. Schilsky

    The Targeted Agent and Profiling Utilization (TAPUR) Study (NCT02693535, registered on February 23, 2016) is a phase II basket trial evaluating the antitumor activity of commercially available targeted agents in patients with advanced cancers harboring genomic alterations known to be drug targets. We analyzed the prevalence of targetable gene alterations in the diverse population of patients participating in this study. We assessed 978 gene alterations or other biomarkers across sex, age, race, ethnicity, BMI category, smoking status, Eastern Cooperative Oncology Group performance status, and cancer type in 3448 registrants. We report a higher prevalence of genomic targets of FDA-approved therapies for various cancers, including PDGRFA in Hispanic versus non-Hispanic registrants and JAK2 in Asian versus White registrants. This study reinforces the importance of recruiting diverse populations of patients to clinical trials and provides evidence that may inform the development of strategic treatment plans that consider patient demographics in addition to tumor characteristics. Clinicaltrials.gov NCT02693535.


  • Open Access

    Afatinib in patients with solid tumors with neuregulin 1 (NRG1) fusions: a case series from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study

    by J. Rodon, M. Rothe, P.K. Mangat, E. Garrett-Mayer, T.L. Cannon, E. Hobbs, G.P. Kalemkerian, D.C. Hinshaw, A. Gregory, G.N. Grantham, et al.


  • Palbociclib in Patients With Head and Neck Cancer and Other Tumors With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study

    by Francis P. Worden, Evan Pisick, Michael Rothe, Pam K. Mangat, Elizabeth Garrett-Mayer, Maged F. Khalil, Daniel R. Carrizosa, Jessica R. Bauman, Rom S. Leidner, Herbert L. Duvivier, et al.

    PURPOSE: Targeted Agent and Profiling Utilization Registry is a phase II basket trial evaluating the antitumor activity of commercially available targeted agents in patients with advanced cancer and targetable genomic alterations. Two cohorts of patients with cyclin-dependent kinase inhibitor 2A ( CDKN2A )–mutated tumors treated with palbociclib are reported: one with head and neck cancer (HNC) with both squamous and nonsquamous cell histologies, and one with histology-pooled (HP) cancers. METHODS: Eligible patients had measurable disease, Eastern Cooperative Oncology Group performance status 0-2, adequate organ function, and no standard treatment options. The primary end point was disease control (DC), defined as objective response (OR) or stable disease (SD) of at least 16+ weeks duration. For the HNC cohort, Simon's two-stage design with a null DC rate of 15% versus 35% (power = 0.85; α = .10) was used. For the HP cohort, the null hypothesis of a DC rate of 15% was rejected if the lower limit of a one-sided 90% CI was >15%. Secondary end points included OR, safety, progression-free survival, overall survival, duration of response, and duration of SD RESULTS: Seventy patients with HNC (N = 28) or HP cancers (N = 42) were treated with palbociclib. For the HNC cohort, DC and OR rates were 40% (one-sided 90% CI, 27 to 100) and 4% (95% CI, P = .002). For the HP cohort, DC and OR rates were 13% (one-sided 90% CI, 6 to 100) and 5% (95% CI, CDKN2A alterations, but not in the HP cohort.


  • Pertuzumab Plus Trastuzumab in Patients With Biliary Tract Cancer With ERBB2/3 Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study

    by Timothy L. Cannon, Michael Rothe, Pam K. Mangat, Elizabeth Garrett-Mayer, Vi K. Chiu, Jimmy Hwang, Namrata Vijayvergia, Olatunji B. Alese, Elie G. Dib, Herbert L. Duvivier, et al.

    PURPOSE: Targeted Agent and Profiling Utilization Registry is a phase II basket trial evaluating the antitumor activity of commercially available targeted agents in patients with advanced cancer and genomic alterations known to be drug targets. Results of a cohort of patients with biliary tract cancer (BTC) with ERBB2/3 amplification, overexpression, or mutation treated with pertuzumab plus trastuzumab are reported. METHODS: Eligible patients had advanced BTC, measurable disease (RECIST v1.1), Eastern Cooperative Oncology Group performance status 0-2, adequate organ function, tumors with ERBB2/3 alterations, and a lack of standard treatment options. Simon's two-stage design was used with a primary end point of disease control (DC), defined as objective response (OR) or stable disease of at least 16+ weeks duration (SD16+) according to RECIST v1.1. Secondary end points included OR, progression-free survival, overall survival, duration of response, duration of stable disease, and safety. RESULTS: Twenty-nine patients were enrolled from February 2017 to January 2022, and all had advanced BTC with an ERBB2/3 alteration. One patient was not evaluable for efficacy. One complete response, eight partial responses, and two SD16+ were observed for DC and OR rates of 40% (90% CI, 27 to 100) and 32% (95% CI, 16 to 52), respectively. The null hypothesis of 15% DC rate was rejected ( P = .0015). Four patients had at least one grade 3 adverse event (AE) or serious AE at least possibly related to treatment: anemia, diarrhea, infusion-related reaction, and fatigue. CONCLUSION: Pertuzumab plus trastuzumab met prespecified criteria to declare a signal of activity in patients with BTC and ERBB2/3 amplification, overexpression, or mutation.